Trial
NCT06202521
CX-4945 in Viral Community Acquired Pneumonia
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Senhwa Biosciences, Inc.
Collaborators
—
Condition
Community-acquired Pneumonia
Intervention
CX-4945 (SARS-CoV-2 domain)
Why stopped
The trial ended early in March 2025 due to changes in disease epidemiology, affecting patient availability and recruitment feasibility.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-01-08